CD4 and non-Hodgkin lymphoma: In this study, we measured plasma levels of CD20+ EVs and compared those concentrations with clinical and pathologic features of AIDS-NHL trial participants part of the AMC-034 trial, such as HIV viral load, CD4+ T-cell count, response to treatment, and patient outcome measures, including overall survival and progression-free survival.